X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4) 4
aged (3) 3
female (3) 3
index medicus (3) 3
male (3) 3
middle aged (3) 3
treatment outcome (3) 3
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
chemotherapy (2) 2
colorectal cancer (2) 2
colorectal neoplasms - drug therapy (2) 2
colorectal neoplasms - genetics (2) 2
colorectal neoplasms - pathology (2) 2
disease-free survival (2) 2
drug administration schedule (2) 2
fluorouracil - administration & dosage (2) 2
folinic acid (2) 2
gastroenterology & hepatology (2) 2
kras (2) 2
leucovorin - administration & dosage (2) 2
metastatic colorectal cancer (2) 2
mutation (2) 2
oncology (2) 2
predictive value of tests (2) 2
proto-oncogene proteins - genetics (2) 2
proto-oncogene proteins p21 (2) 2
ras proteins - genetics (2) 2
1st-line treatment (1) 1
5-fluorouracil (1) 1
5-氟尿嘧啶 (1) 1
adult (1) 1
aged, 80 and over (1) 1
analysis (1) 1
angiogenesis inhibitors - administration & dosage (1) 1
angiogenesis inhibitors - adverse effects (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
animals (1) 1
anti-epidermal (1) 1
anti-epidermal growth factor receptor (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
bevacizumab (1) 1
bevacizumab - administration & dosage (1) 1
bevacizumab - adverse effects (1) 1
bevacizumab - therapeutic use (1) 1
biomarkers (1) 1
biomarkers, tumor - antagonists & inhibitors (1) 1
biomarkers, tumor - genetics (1) 1
biomarkers, tumor - metabolism (1) 1
braf mutation (1) 1
camptothecin - administration & dosage (1) 1
camptothecin - analogs & derivatives (1) 1
cancer (1) 1
cancer patients (1) 1
cancer therapies (1) 1
carcinoma, hepatocellular - drug therapy (1) 1
cardiovascular (1) 1
care and treatment (1) 1
case report (1) 1
cetuximab (1) 1
cetuximab plus irinotecan (1) 1
clinical study (1) 1
colonoscopy (1) 1
colorectal neoplasms - enzymology (1) 1
colorectal neoplasms - immunology (1) 1
colorectal neoplasms - mortality (1) 1
colorectal-cancer (1) 1
combination chemotherapy (1) 1
combined modality therapy (1) 1
cytotoxicity (1) 1
digestive system diseases (1) 1
dihydropyrimidine-dehydrogenase (1) 1
disease progression (1) 1
dna mutational analysis (1) 1
dna-damage (1) 1
doxorubicin - administration & dosage (1) 1
doxorubicin - adverse effects (1) 1
doxorubicin - analogs & derivatives (1) 1
drug therapy, combination (1) 1
end-point (1) 1
epidermal growth factor receptor (1) 1
factor (1) 1
fluorouracil (1) 1
fluorouracil - adverse effects (1) 1
follow-up studies (1) 1
genetic predisposition to disease (1) 1
genetic testing (1) 1
growth (1) 1
growth-factor receptor (1) 1
guidelines (1) 1
hematology, oncology and palliative medicine (1) 1
hepatocellular carcinoma (1) 1
immunohistochemistry (1) 1
independent prognostic-factor (1) 1
infusions, intravenous (1) 1
intention to treat analysis (1) 1
italy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2016
Abstract The late worsening of non-severe tricuspid regurgitation (TR) following mitral valve surgery is a relevant clinical problem that can lead to high-risk... 
Cardiovascular
Journal Article
世界胃肠病学杂志:英文版(电子版), ISSN 1007-9327, 2014, Volume 20, Issue 29, pp. 9732 - 9743
Journal Article
世界胃肠病学杂志:英文版, ISSN 1007-9327, 2007, Volume 13, Issue 48, pp. 6553 - 6557
Journal Article
Journal Article
World journal of clinical cases, ISSN 2307-8960, 11/2014, Volume 2, Issue 11, pp. 717 - 723
The management of patients with non-progressive metastatic colorectal cancer after six months of treatment has not yet been codified. The most relevant... 
Maintenance | Metastatic colorectal cancer | Case Report | Bevacizumab
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.